At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 110 enrolled
Drug / intervention
Click Digital Therapeuticdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel-Group, Virtual Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics for the Prevention of Episodic Migraine in Late Adolescents and Adults Currently Receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
In Brief
A Phase 3 clinical trial evaluating Click Digital Therapeutic for Migraine and 3 related conditions. Completed, enrolled 110 participants across 1 site.
Detailed Summary
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Episodic Migraine, Headache, Headache, Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
Enrollment StartJul 2023
First PostedAug 2023
Primary CompletionMay 2024
Study CompletionJun 2024
TodayJul 2026
First PostedAug 22, 2023
Enrollment StartJul 21, 2023
Primary CompletionMay 21, 2024
Study CompletionJun 5, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.9 years ago
Interventions
Click Digital Therapeuticdevice
Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy